NCT00596258View on ClinicalTrials.gov

A Two-Stage Phase 2 Study Of A-007 Topical Gel in High-Grade Squamous Intraepithelial Lesions (HSIL)

PHASE2CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

November 30, 2007

Primary Completion Date

July 31, 2008

Study Completion Date

August 31, 2008

Conditions
Cervical Intraepithelial NeoplasiaUterine Cervical Dysplasia
Interventions
DRUG

A-007

applied topically for two 28-day cycles of 14 consecutive days of treatment each to the uterine cervix

Trial Locations (5)

10016

NYU School of Medicine, New York

10461

Montefiore Medical Center-Weiler Division Dept of OB/GYN & Women's Health, The Bronx

33437

Visions Clinical Research, Boynton Beach

85712

Visions Clinical Research-Tucson, Tucson

92629

Robin Black OGNP, Costa Mesa

Sponsors
All Listed Sponsors
lead

Tigris Pharmaceuticals

INDUSTRY

NCT00596258 - A Two-Stage Phase 2 Study Of A-007 Topical Gel in High-Grade Squamous Intraepithelial Lesions (HSIL) | Biotech Hunter | Biotech Hunter